Lipid-lowering HMG-CoA reductase inhibitors (statins), which are used in vast groups of patients for the prevention and treatment of cardiovascular diseases, are one of the pharmaceutical classes that have been proposed as possible preventive and/or adjuvant treatment of severe COVID-19. This evidence concerns the gene HMGCR and COVID-19.